The sharp decline in the rate of new breast cancer cases in 2003 may be related to a national decline in the use of hormone replacement therapy (HRT), according to a new report in the April 19, 2007, issue of the New England Journal of Medicine.
An extended analysis of cancer rates reinforces a strong association between use of hormone replacement therapy and increased breast cancer incidence, according to research led by scientists at the University of Texas M. D. Anderson Cancer Center and published in the April 19 issue of the New England Journal of Medicine.
Following a report of the analysis of data from the SEER registries of the NCI, showing that the incidence of breast cancer fell by 6.7 percent in 2003 in the US, and the suggestion that the data might be linked to the decrease in the use of postmenopausal hormones, the IMS advises caution in linking these two trends and recommends that hormone therapy be prescribed whenever indicated.
Women can encounter environmental factors that increase their risk of breast cancer at various periods of their physical development, beginning before birth and extending until menopause.
Up to 15 percent of couples of childbearing age struggle with the heartache of infertility. Now there is the promise of new hope with Cornell researchers’ identification of a mutation in a gene that causes male infertility in mice.
Measuring a man?s daily calcium intake is an effective way of identifying prostate cancer patients with a higher than average risk of osteoporosis, according to the April issue of the urology journal BJU International.
A new study published in the Journal of the American Medical Association found no increased risk of heart attack for women in their 50s who were taking HRT.
A study of herbal kelp supplements led by UC Davis public health expert Marc Schenker concludes that its medicinal use may cause inadvertent arsenic poisoning and health dangers for consumers, especially when overused. Schenker and two researchers evaluated nine over-the-counter herbal kelp products and found higher than acceptable arsenic levels in eight of them.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), provides comment on a re-analysis of pooled data from both hormone therapy arms of the Women?s Health Initiative (WHI) Study published in the Journal of the American Medical Association.
Women who initiate hormone therapy closer to menopause tend to have a reduced risk of coronary heart disease compared to women who begin treatment further from menopause, but researchers did not find this reduced risk was statistically significant, according to a study in the April 4 issue of JAMA.